The DOI matches its Crossref record.
Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity
Abstract
Perforin- and Fas-based cytolytic pathways are two major mechanisms of cell-mediated cytotoxicity. Recently, we have shown that an inhibitor of vacuolar type H+-ATPase, concanamycin A (CMA), inhibits perforin-based cytotoxic activity, mostly due to accelerated degradation of perforin by an increase in the pH of lytic granules. Here we show that CMA failed to inhibit the cytolytic activity of CD4+ CTL clone and perforin-deficient CD8+ CTL clone, which exclusively mediate Fas-based cytotoxicity, although CMA inhibited acidification and induced drastic vacuolation of cytoplasmic granules in these clones. In a wide range of alloantigen-specific CTL, a significant amount of the lysis of Con A blasts from normal mice and of Fas-positive tumor cells remained unaffected even in excess concentrations of CMA. However, CMA almost completely inhibited the lysis of Con A blasts from lpr mice and of Fas low expressing or negative tumor cells. Cytolysis by alloantigen-specific CD8+ CTL derived from gld mice was completely prevented by CMA. Furthermore, CMA-insensitive cytolysis exerted by CD8+ CTL clone was completely inhibitable by soluble Fas molecules. Thus, these data clearly indicate not only that CMA-insensitive cytolysis mediated by alloantigen-specific CTL is Fas dependent, but also that CMA is a selective inhibitor to block only the perforin-based killing pathway. In contrast, brefeldin A blocked the Fas-based cytotoxicity, but only marginally reduced the perforin-based cytotoxicity. Moreover, CMA and brefeldin A in combination completely abrogated all cytolytic activity of alloantigen-specific CTL. Taken together, these results reveal that CTL mainly exert perforin-based cytotoxicity and complementary Fas-based cytotoxicity, and that CMA is a powerful tool to clarify the contributions of the two distinct cytolytic pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Requirement for V α 14 NKT Cells in IL-12-Mediated Rejection of Tumors
Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., & Taniguchi, M. (1997) · Science · doi:10.1126/science.278.5343.1623 · Cited by 1,237
Chemistry and Biology of Roseophilin and the Prodigiosin Alkaloids: A Survey of the Last 2500 Years
Fürstner, A. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200300582 · Cited by 827
Characterization of CD4+ CTLs Ex Vivo
Appay, V., Zaunders, J. J., Papagno, L., Sutton, J., Jaramillo, A., Waters, A., Easterbrook, P., Grey, P., Smith, D., McMichael, A. J., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5954 · Cited by 545
Critical contribution of liver natural killer T cells to a murine model of hepatitis
Takeda, K., Hayakawa, Y., Van Kaer, L., Matsuda, H., Yagita, H., & Okumura, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040566697 · Cited by 539
Kayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., & Yagita, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1451 · Cited by 479
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Sato, H., Kondo, E., Harada, M., Koseki, H., Nakayama, T., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5690 · Cited by 476
Mention, J.-J., Ben Ahmed, M., Bègue, B., Barbe, U., Verkarre, V., Asnafi, V., Colombel, J.-F., Cugnenc, P.-H., Ruemmele, F. M., Mcintyre, E., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01047-3 · Cited by 462
Interleukin-18: A Novel Cytokine That Augments Both Innate and Acquired Immunity
(1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60389-2 · Cited by 450
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
Stary, G., Bangert, C., Tauber, M., Strohal, R., Kopp, T., & Stingl, G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070021 · Cited by 363
Medema, J. P., de Jong, J., Peltenburg, L. T. C., Verdegaal, E. M. E., Gorter, A., Bres, S. A., Franken, K. L. M. C., Hahne, M., Albar, J. P., Melief, C. J. M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201398198 · Cited by 356
Expression and Function of TNF-Related Apoptosis-Inducing Ligand on Murine Activated NK Cells
Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H., Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., & Yagita, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1906 · Cited by 340
Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein
Medema, J. P., de Jong, J., van Hall, T., Melief, C. J. M., & Offringa, R. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.7.1033 · Cited by 330
Fas/FasL-dependent Apoptosis of Alveolar Cells after Lipopolysaccharide-induced Lung Injury in Mice
KITAMURA, Y., HASHIMOTO, S., MIZUTA, N., KOBAYASHI, A., KOOGUCHI, K., FUJIWARA, I., & NAKAJIMA, H. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.3.2003065 · Cited by 298
Brown, D. M., Dilzer, A. M., Meents, D. L., & Swain, S. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.2888 · Cited by 282
Hanon, E., Hall, S., Taylor, G. P., Saito, M., Davis, R., Tanaka, Y., Usuku, K., Osame, M., Weber, J. N., & Bangham, C. R. M. (2000) · Blood · doi:10.1182/blood.v95.4.1386.004k22_1386_1392 · Cited by 276
Antiviral response by natural killer cells throughTRAIL gene induction by IFN-α/β
Sato, K., Hida, S., Takayanagi, H., Yokochi, T., Kayagaki, N., Takeda, K., Yagita, H., Okumura, K., Tanaka, N., Taniguchi, T., et al. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200111)31:11<3138::aid-immu3138>3.0.co;2-b · Cited by 271
Monleón, I., Martínez-Lorenzo, M. J., Monteagudo, L., Lasierra, P., Taulés, M., Iturralde, M., Piñeiro, A., Larrad, L., Alava, M. A., Naval, J., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.6736 · Cited by 266
Curtsinger, J. M., Lins, D. C., Johnson, C. M., & Mescher, M. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4392 · Cited by 90
“To confirm that the cytolytic activity being examined in these experiments was perforin-dependent, we examined inhibition by concanamycin A, which causes degradation of perforin in the granules, and therefore specifically inhibits perforin-dependent killing but not Fas ligand-dependent killing (28).”
BackgroundGrabert, R. C., Cousens, L. P., Smith, J. A., Olson, S., Gall, J., Young, W. B., Davol, P. A., & Lum, L. G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2005 · Cited by 79
Metadata
- Authors
- Kataoka, T., Shinohara, N., Takayama, H., Takaku, K., Kondo, S., Yonehara, S., & Nagai, K.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-05
- Volume
- 156
- Issue
- 10
- Pages
- 3678-3686
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1943839210
- Cited by
- 377
- References
- 0
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.